Semiconductors & Semiconductor Capital Equipment
ThermiGen LLC, a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications, completed its previously announced sale to Almirall, S.A., a global pharmaceutical company based in Barcelona, Spain. In September 2015, Almirall acquired a minority stake in ThermiGen for $5 million representing 7.7% of the share capital of the company and paid $2.5 million in exchange of a call option right to acquire up to 100% of the company for an Enterprise Value of approximately $80 million. The call option to acquire 100% of the share capital of ThermiGen LLC was exercised by Almirall. Needham & Company acted as the exclusive financial advisor to ThermiGen LLC.
ThermiGen LLC is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF®, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.